HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Legislation Cosmetics Beauty

Mandatory AE Reporting In Supplement Space Offers Glimpse Of Possible Cosmetic Future

This article was originally published in The Rose Sheet

  • News

Executive Summary

Reports of serious adverse events in the dietary supplement industry have increased exponentially since reporting was made mandatory in 2008, and FDA warning letters citing failures to report have been on the rise as companies labor to keep up with investigations and reporting duties. Similar challenges could lie ahead for the cosmetics industry under proposed bills in the US House and Senate.

Table

View full table

Advertisement

Related Content

HBW Insight
Cosmetics Recalls For August-October Period Have One Familiar Thing In Common: All Were Voluntary
HBW Insight
Supplement AER Numbers Could Raise False Alarm About Product Safety
HBW Insight
Adverse Event Data Could Tip Scales In Cosmetics Regulatory Reform
HBW Insight
FDA To Congressman Pallone: Probe Into WEN Conditioner AEs Continues
HBW Insight
FDA's Cosmetic AE Data Begs Question: What If Reporting Were Mandatory?
HBW Insight
Feinstein, EWG Gunning For Spring Senate Hearing On Cosmetics Bill
HBW Insight
Supplement Industry Offers Cautionary Tale For Mandatory Cosmetic GMPs
Pink Sheet
Supplement GMP Inspections Reveal Adverse Event Reports, Prompting Warning Letters
Pink Sheet
Supplement AER Compliance Costs Exceed FDA Estimates – Industry
Pink Sheet
FDA Says Supplement Adverse Event Under-Reporting Should Feed Growth

Topics

Advertisement
Tags:
Legislation Cosmetics Beauty
UsernamePublicRestriction

Register

RS019831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By